Molecular evolution of HIV-1 CRF01_AE Env in Thai patients

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Boonchawalit, Samatchaya ^a   Jullaksorn, Duangrat ^b   Uttiyoung, Jiraporn ^c   Yowang, Amara ^c   Krathong, Nongkran ^d   Chautrakul, Sununta ^d   Yamashita, Akifumi ^e   Ikuta, Kazuyoshi ^f   Roobsoong, Amornsak ^d   Kanitvittaya, Sangkom ^c   Sawanpanyalert, Pathom ^b   Kameoka, Masanori ^a,f  

^a Thailand Japan Research Collaboration Center on Emerging and Re emerging Infections RCC ERI   (Thailand)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

^c Regional Medical Science Center Chiangrai   (Thailand)

^d Mae Soay Hospital   (Thailand)

^e TOHOKU UNIVERSITY   (Japan)

^f OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; ENVELOPE PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; GUANOSINE; HIV 1 CRF01_AE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; UNCLASSIFIED DRUG; PRIMER DNA;

AMINO TERMINAL SEQUENCE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ENVELOPE GENE; GENE AMPLIFICATION; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; MOLECULAR EVOLUTION; NONHUMAN; PROTEIN FAMILY; PROTEIN GLYCOSYLATION; THAILAND; CD4 LYMPHOCYTE COUNT; GENETICS; NUCLEOTIDE SEQUENCE; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

BASE SEQUENCE; CD4 LYMPHOCYTE COUNT; DNA PRIMERS; EVOLUTION, MOLECULAR; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV-1; THAILAND; VIRAL LOAD;

EID: 80355143404     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027098     Document Type: Article

References (56)

1. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, et al. (2002) Diversity considerations in HIV-1 vaccine selection. Science 296: 2354-2360.
2. Hemelaar J, Gouws E, Ghys PD, Osmanov S, (2011) Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 25: 679-689.
3. Arroyo MA, Phanuphak N, Krasaesub S, Sirivichayakul S, Assawadarachai V, et al. (2010) HIV type 1 molecular epidemiology among high-risk clients attending the Thai Red Cross Anonymous Clinic in Bangkok, Thailand. AIDS Res Hum Retroviruses 26: 5-12.
4. Mansky LM, Temin HM, (1995) Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69: 5087-5094.
5. Sheehy AM, Gaddis NC, Choi JD, Malim MH, (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646-650.
6. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, et al. (2003) DNA deamination mediates innate immunity to retroviral infection. Cell 113: 803-809.
7. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, et al. (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424: 99-103.
8. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, et al. (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424: 94-98.
9. Biasin M, Piacentini L, Lo Caputo S, Kanari Y, Magri G, et al. (2007) Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals. J Infect Dis 195: 960-964.
10. Land AM, Ball TB, Luo M, Pilon R, Sandstrom P, et al. (2008) Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. J Virol 82: 8172-8182.
11. Kieffer TL, Kwon P, Nettles RE, Han Y, Ray SC, et al. (2005) G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol 79: 1975-1980.
12. Jin X, Brooks A, Chen H, Bennett R, Reichman R, et al. (2005) APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia. J Virol 79: 11513-11516.
13. Pace C, Keller J, Nolan D, James I, Gaudieri S, et al. (2006) Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol 80: 9259-9269.
14. Jern P, Russell RA, Pathak VK, Coffin JM, (2009) Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. PLoS Pathog 5: e1000367.
15. Wood N, Bhattacharya T, Keele BF, Giorgi E, Liu M, et al. (2009) HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog 5: e1000414.
16. Wyatt R, Sodroski J, (1998) The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280: 1884-1888.
17. Pantophlet R, Burton DR, (2006) GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24: 739-769.
18. Barbas CF, 3rd, Collet TA, Amberg W, Roben P, Binley JM, et al. (1993) Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. J Mol Biol 230: 812-823.
19. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, et al. (2004) Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 78: 13232-13252.
20. Trkola A, Pomales AB, Yuan H, Korber B, Maddon PJ, et al. (1995) Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 69: 6609-6617.
21. Utachee P, Jinnopat P, Isarangkura-Na-Ayuthaya P, de Silva UC, Nakamura S, et al. (2009) Phenotypic studies on recombinant human immunodeficiency virus type 1 (HIV-1) containing CRF01_AE env gene derived from HIV-1-infected patient, residing in central Thailand. Microbes Infect 11: 334-343.
22. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285-289.
23. Gorny MK, Xu JY, Gianakakos V, Karwowska S, Williams C, et al. (1991) Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein. Proceedings of the National Academy of Sciences of the United States of America 88: 3238-3242.
24. Javaherian K, Langlois AJ, LaRosa GJ, Profy AT, Bolognesi DP, et al. (1990) Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science 250: 1590-1593.
25. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, et al. (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329: 856-861.
26. Posner MR, Hideshima T, Cannon T, Mukherjee M, Mayer KH, et al. (1991) An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. Journal of immunology 146: 4325-4332.
27. Goudsmit J, Boucher CA, Meloen RH, Epstein LG, Smit L, et al. (1988) Human antibody response to a strain-specific HIV-1 gp120 epitope associated with cell fusion inhibition. AIDS 2: 157-164.
28. Sagar M, Wu X, Lee S, Overbaugh J, (2006) Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol 80: 9586-9598.
29. Moore PL, Gray ES, Choge IA, Ranchobe N, Mlisana K, et al. (2008) The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J Virol 82: 1860-1869.
30. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
31. Jullaksorn D, Boonchawalit S, Uttiyoung J, Soonthornsata B, Yowang A, et al. (2010) Sustained appearance of drug resistance-associated mutations in HIV-1 CRF01_AE protease and reverse transcriptase derived from protease inhibitor-naive Thai patients. Southeast Asian J Trop Med Public Health 41: 347-357.
32. Thompson JD, Higgins DG, Gibson TJ, (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22: 4673-4680.
33. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, et al. (2011) MEGA5: Molecular Evolutionary Genetics Analysis using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods. Molecular biology and evolution 28: 2731-2739.
34. Shannon CE, (1948) A Mathematical Theory of Communication. The Bell System Technical Journal 27: 379-423, 623-656.
35. Pond SL, Frost SD, Muse SV, (2005) HyPhy: hypothesis testing using phylogenies. Bioinformatics 21: 676-679.
36. Curran R, Ball JK, (2002) Concordance between semen-derived HIV-1 proviral DNA and viral RNA hypervariable region 3 (V3) envelope sequences in cases where semen populations are distinct from those present in blood. Journal of medical virology 67: 9-19.
37. Ball JK, Holmes EC, Whitwell H, Desselberger U, (1994) Genomic variation of human immunodeficiency virus type 1 (HIV-1): molecular analyses of HIV-1 in sequential blood samples and various organs obtained at autopsy. The Journal of general virology 75 (Pt 4): 67-79.
38. Karlsson AC, Lindback S, Gaines H, Sonnerborg A, (1998) Characterization of the viral population during primary HIV-1 infection. AIDS 12: 839-847.
39. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, et al. (1999) Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 73: 10489-10502.
40. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, et al. (1998) The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393: 705-711.
41. Beale RC, Petersen-Mahrt SK, Watt IN, Harris RS, Rada C, et al. (2004) Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. Journal of molecular biology 337: 585-596.
42. Liddament MT, Brown WL, Schumacher AJ, Harris RS, (2004) APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Current biology: CB 14: 1385-1391.
43. Lamers SL, Sleasman JW, She JX, Barrie KA, Pomeroy SM, et al. (1993) Independent variation and positive selection in env V1 and V2 domains within maternal-infant strains of human immunodeficiency virus type 1 in vivo. J Virol 67: 3951-3960.
44. Yamaguchi Y, Gojobori T, (1997) Evolutionary mechanisms and population dynamics of the third variable envelope region of HIV within single hosts. Proc Natl Acad Sci U S A 94: 1264-1269.
45. Frost SD, Gunthard HF, Wong JK, Havlir D, Richman DD, et al. (2001) Evidence for positive selection driving the evolution of HIV-1 env under potent antiviral therapy. Virology 284: 250-258.
46. Bagnarelli P, Mazzola F, Menzo S, Montroni M, Butini L, et al. (1999) Host-specific modulation of the selective constraints driving human immunodeficiency virus type 1 env gene evolution. J Virol 73: 3764-3777.
47. Rong R, Li B, Lynch RM, Haaland RE, Murphy MK, et al. (2009) Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS pathogens 5: e1000594.
48. Utachee P, Jinnopat P, Isarangkura-Na-Ayuthaya P, de Silva UC, Nakamura S, et al. (2009) Genotypic Characterization of CRF01_AE env Genes Derived from Human Immunodeficiency Virus Type 1-Infected Patients Residing in Central Thailand. AIDS Res Hum Retroviruses 25: 229-236.
49. Naganawa S, Yokoyama M, Shiino T, Suzuki T, Ishigatsubo Y, et al. (2008) Net positive charge of HIV-1 CRF01_AE V3 sequence regulates viral sensitivity to humoral immunity. PLoS ONE 3: e3206.
50. Dieltjens T, Loots N, Vereecken K, Grupping K, Heyndrickx L, et al. (2009) HIV type 1 subtype A envelope genetic evolution in a slow progressing individual with consistent broadly neutralizing antibodies. AIDS Res Hum Retroviruses 25: 1165-1169.
51. Archary D, Gordon ML, Green TN, Coovadia HM, Goulder PJ, et al. (2010) HIV-1 subtype C envelope characteristics associated with divergent rates of chronic disease progression. Retrovirology 7: 92.
52. Gnanakaran S, Lang D, Daniels M, Bhattacharya T, Derdeyn CA, et al. (2007) Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120. J Virol 81: 4886-4891.
53. Rong R, Gnanakaran S, Decker JM, Bibollet-Ruche F, Taylor J, et al. (2007) Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. J Virol 81: 5658-5668.
54. Mens H, Pedersen AG, Jorgensen LB, Hue S, Yang Y, et al. (2007) Investigating signs of recent evolution in the pool of proviral HIV type 1 DNA during years of successful HAART. AIDS Res Hum Retroviruses 23: 107-115.
55. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220.
56. Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, et al. (2010) Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate. PLoS ONE 5: e13983.